Meridian Bioscience, Inc. (NASDAQ:VIVO) CEO John P. Kenny acquired 20,000 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was purchased at an average price of $7.73 per share, with a total value of $154,600.00. Following the acquisition, the chief executive officer now owns 198,324 shares of the company’s stock, valued at approximately $1,533,044.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
VIVO stock opened at $8.50 on Thursday. Meridian Bioscience, Inc. has a fifty-two week low of $7.63 and a fifty-two week high of $19.81. The business’s 50-day moving average is $9.51 and its two-hundred day moving average is $10.66. The company has a debt-to-equity ratio of 0.40, a quick ratio of 4.75 and a current ratio of 6.93. The company has a market cap of $337.42 million, a price-to-earnings ratio of 12.50 and a beta of 0.37.
Meridian Bioscience (NASDAQ:VIVO) last posted its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. Meridian Bioscience had a return on equity of 15.89% and a net margin of 12.13%. The company had revenue of $50.80 million for the quarter, compared to the consensus estimate of $50.57 million. During the same quarter in the prior year, the company earned $0.20 earnings per share. Meridian Bioscience’s revenue was down 4.3% on a year-over-year basis. Equities analysts predict that Meridian Bioscience, Inc. will post 0.31 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. UBS Asset Management Americas Inc. lifted its holdings in Meridian Bioscience by 4.2% in the second quarter. UBS Asset Management Americas Inc. now owns 28,530 shares of the company’s stock valued at $339,000 after acquiring an additional 1,163 shares during the period. Swiss National Bank raised its stake in shares of Meridian Bioscience by 2.2% in the second quarter. Swiss National Bank now owns 79,000 shares of the company’s stock worth $939,000 after buying an additional 1,700 shares during the period. 6 Meridian raised its stake in shares of Meridian Bioscience by 4.9% in the second quarter. 6 Meridian now owns 42,384 shares of the company’s stock worth $504,000 after buying an additional 1,964 shares during the period. Coastal Capital Group Inc. bought a new position in shares of Meridian Bioscience in the second quarter worth about $25,000. Finally, Pacer Advisors Inc. raised its stake in shares of Meridian Bioscience by 19.0% in the third quarter. Pacer Advisors Inc. now owns 14,734 shares of the company’s stock worth $140,000 after buying an additional 2,354 shares during the period. 88.49% of the stock is currently owned by institutional investors.
A number of equities research analysts have recently commented on the company. BidaskClub raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, October 16th. ValuEngine raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Zacks Investment Research cut Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. Finally, Canaccord Genuity reissued a “sell” rating and issued a $9.00 target price on shares of Meridian Bioscience in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. Meridian Bioscience has a consensus rating of “Hold” and a consensus price target of $11.25.
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Featured Article: Google Finance Portfolio
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.